Cardlytics (CDLX) Plunge 11.80% as Net Loss, Insider Selling, and Activist Moves Spark Volatility

The share price of Cardlytics (CDLX) fell to its lowest level since September 2025 today, with an intraday decline of 13.09%. The stock closed down 11.80%, reflecting heightened market uncertainty and sensitivity to recent corporate developments and institutional activity.

Institutional investors showed mixed signals, with Empower Advisory Group, General Equity Holdings, and Tower Research Capital acquiring shares in late August and September, while Landscape Capital Management reduced its stake earlier in the month. The appointment of Alex Mishurov to the board on September 19 added to strategic uncertainty, as activist investor activity emerged as a potential catalyst for operational changes. Meanwhile, insider selling on September 13 triggered a sharp selloff, underscoring the stock’s volatility amid conflicting signals from corporate actions.

Second-quarter earnings highlighted a 1.86% revenue beat but a net loss, prompting cautious investor sentiment. Analysts remained divided, with Needham maintaining a Buy rating and JP Morgan advising a Neutral stance. The company’s partnerships with major U.S. banks were cited as a key growth driver, though profitability concerns persisted amid macroeconomic challenges. Institutional buying and strategic positioning provided brief optimism, but conflicting signals from analysts and corporate actions left the stock vulnerable to further swings.